Fatih TEMOÇİN, Şeyma Betül KAYHAN, Levent ŞENSOY, Tuba KURUOĞLU, Aynur ATİLLA, Esra TANYEL

Karbapenem dirençli Klebsiella pneumonia’nın neden olduğu idrar yolu enfeksiyonları: monoterapi ya da kombineterapi?

Amaç: Bu çalışmada karbapenem dirençli Klebsiella pneumoniae'nın neden olduğu sağlık hizmeti ilişkili üriner sistem enfeksiyonlarını değerlendirildi. Gereç yöntem: Çalışmaya karbapenem dirençli Klebsiella pneumoniae'nın (CR-Kp)neden olduğu sağlık hizmeti ilişkili idrar yolu enfeksiyonu tanısı almış 134 hasta dahil edildi. Hastaların demografik özellikleri, başlangıç klinik durumları, komorbiditeleri ve Charlson komorbidite indeksi kaydedildi. Ayrıca meropenemin CR-Kp izolatları üzerindeki MİK değerleri, tedavi rejimleri, tedaviye klinik ve mikrobiyolojik yanıtları ile hastaların 14 ve 28 günlük mortalite oranları incelendi. Bulgular: 14 günlük mortalite oranı %34,3, 28 günlük mortalite oranı ise %42,5 bulundu. Ölen hastaların yaş ortalaması anlamlı olarak daha yüksekti (p=0,03). Benzer şekilde ölen hastalarda Charlson komorbidite indeksi (p=0,03) ve qSOFA değerleri (p=0,00) anlamlı olarak yüksekti. Yaşayan hastalarda mikrobiyolojik yanıt oranı daha yüksekti (p=0,01) ve bakteriyemi açısından gruplar arasında fark yoktu (p=0,29). Sepsisli hasta grubunda kombine antibiyoterapinin 14 ve 28 günlük mortalite oranlarını monoterapiye göre anlamlı olarak daha üstün olduğu saptandı (sırasıyla p=0,00 ve p=0,04). Ancak sepsis olmayan hasta gruplarında monoterapi ve kombinasyon tedavisi arasında anlamlı fark yoktu (sırasıyla p=0,72 ve p=0,36). Sonuç: Çalışmamız, CR-Kp'nin neden olduğu üriner sistem enfeksiyonlarının tedavisinde sepsisli hastalarda kombinasyon tedavisinin, sepsis olmayan hastalarda ise in vitro aktif bir ajanla monoterapinin kullanılabileceğini desteklemektedir.

Anahtar Kelimeler:

Klebsiella pneumonia, karbapenem dirençli, sağlık hizmetiyle ilişkili enfeksiyon, idrar yolu enfeksiyonu

Urinary tract infections caused by carbapenem-resistant Klebsiella pneumonia: monotherapy or combined therapy?

Purpose: In this study, we evaluated healthcare-associated urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. Materials and methods: The study included 134 patients, diagnosed with healthcare-associated urinary tract infection caused by carbapenem-resistant Klebsiella pneumoniae. Demographic features, initial clinical conditions, comorbidities, and Charlson’s comorbidity index of the patients were recorded. In addition, the MIC values of meropenem on the CR-Kp isolates, treatment regimens, clinical and microbiological responses to the treatment, as well as 14- and 28-day mortality rates of the patients, were reviewed. Results: The 14-day mortality rate was 34.3%, and the 28-day mortality rate was 42.5%. The mean age of the patients who died was significantly higher (p=0.03). Similarly, Charlson’s comorbidity index (p=0.03) and the qSOFA values (p=0.00) were significantly higher in the patients who died. The microbiological response rate was higher in the patients who survived (p=0.01) with no difference in bacteremia between the groups (p=0.29). It was found that combined antibiotherapy provided significantly better 14- and 28-day mortality rates compared to monotherapy in the group of patients with sepsis (p=0.00 and p=0.04, respectively). However, monotherapy and combination therapy in groups of patients without sepsis were insignificant (p=0.72 and p=0.36, respectively). Conclusion: Our study supports the use of combination therapy in patients with sepsis, and monotherapy with an in-vitro active agent may be used for patients without sepsis in the treatment of urinary tract infections caused by CR-KP.

Keywords:

Klebsiella pneumoniae, carbapenem-resistant, healthcare-associated infection;, urinary tract infection,

PDF

___

1. Munoz Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013;13:785-796. https://doi.org/10.1016/S1473-3099(13)70190-7
2. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-236. https://doi.org/10.1016/S1473-3099(09)70054-4
3. Logan LK, Weinstein RA. The Epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 2017;215:28-36. https://doi.org/10.1093/infdis/jiw282
4. Saeed NK, Alkhawaja S, Azam N, Alaradi K, Al Biltagi M. Epidemiology of carbapenem-resistant Enterobacteriaceae in a tertiary care center in the Kingdom of Bahrain. J Lab Physicians 2019;11:111-117. https://doi.org/10.4103/JLP.JLP_101_18
5. Eser F, Yılmaz GR, Güner R, Koçak Tufan Z. Carbapenem-resistant Enterobacteriaceae infections: risk factors. Akdeniz Medical Journal 2018;2:144-151. https://doi.org/10.17954/amj.2018.133
6. World Health Organization (WHO). List of bacteria for which new antibiotics are urgently needed. WHO 2017 Available at: https://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed February 17, 2020
7. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob 2017;16:18-19. https://doi.org/10.1186/s12941-017-0191-3
8. Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill 2014;19:20939. https://doi.org/10.2807/1560-7917.es2014.19.42.20939
9. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016;29:321-347. https://doi.org/10.1128/CMR.00068-15
10. Grabein B, Graninger W, Rodriguez Bano J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future. systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 2017;23:363-372. https://doi.org/10.1016/j.cmi.2016.12.005
11. Livermore DM, Warner M, Jamrozy D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015;59:5324-5330. https://doi.org/10.1128/AAC.00678-15
12. Alm RA, Johnstone MR, Lahiri SD. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother 2015;70:1420-1428. https://doi.org/10.1093/jac/dku568
13. Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014;20:117-123. https://doi.org/10.1111/1469-0691.12341
14. Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 2017;72:29-39. https://doi.org/10.1093/jac/dkw377
15. Paul M, Daikos GL, Durante Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018;18:391-400. https://doi.org/10.1016/S1473-3099(18)30099-9
16. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015;70:2133-2143. https://doi.org/10.1093/jac/dkv086
17. Peri AM, Doi Y, Potoski BA, Harris PNA, Paterson DL, Righi E. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn Microbiol Infect Dis 2019;94:413-425. https://doi.org/10.1016/j.diagmicrobio.2019.01.020
18. Papst L, Beovic B, Pulcini C, et al. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect 2018;24:1070-1076. https://doi.org/10.1016/j.cmi.2018.01.015
19. Balkan II, Aygun G, Aydin S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis 2014;26:51-56. https://doi.org/10.1016/j.ijid.2014.05.012
20. Falcone M, Russo A, Lacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect 2016;22:444-450. https://doi.org/10.1016/j.cmi.2016.01.016
21. Giannella M, Trecarichi EM, Giacobbe DR, et al. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents 2018;51:244-248. https://doi.org/10.1016/j.ijantimicag.2017.08.019
22. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012;18:439-448. https://doi.org/10.1111/j.1469-0691.2012.03823.x
23. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 27th ed. Wayne, PA. CLSI 2017;100:27-28.
24. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. EUCAST 2016 Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_ for_MIC_determination_of_colistin_March_2016.pdf. Accessed June 5, 2020
25. Tansarli GS, Papaparaskevas J, Balaska M, et al. Colistin resistance in carbapenemase-producing Klebsiella pneumoniae bloodstream isolates: evolution over 15 years and temporal association with colistin use by time series analysis. Int J Antimicrob Agents 2018;52:397-403. https://doi.org/10.1016/j.ijantimicag.2018.06.012